Case Report

Thrombotic Microangiopathy Associated With Tacrolimus in Lung Transplantation☆

Juan Pablo Reig Mezquida,a,☆ Amparo Solé Jover,b Emilio Ansótegui Barrera,b Juan Escrivá Peiró,b Maria Desamparados Pastor Colom,b Juan Pastor Guillemc

a Servicio de Neumología, Hospital Universitari i Politècnic la Fe, Valencia, Spain
b Unidad de Trasplante Pulmonar, Hospital Universitari i Politècnic la Fe, Valencia, Spain
c Servicio de Cirugía Torácica, Hospital Universitari i Politècnic la Fe, Valencia, Spain

A R T I C L E   I N F O

Article history:
Received 26 May 2014
Accepted 7 July 2014
Available online 25 March 2015

Keywords:
Thrombotic microangiopathy
Lung transplantation
Tacrolimus
Hemolytic uremic syndrome

A B S T R A C T

Thrombotic microangiopathy (TMA) is a rare complication associated with the use of calcineurin inhibitors in lung transplantation, irrespective of the underlying disease of the graft recipient. It usually occurs in incomplete forms, complicating and delaying diagnosis until damage is already irreversible. It is unrelated to time from transplantation and often presents with concomitant infection, which tends to confound diagnosis. The cases discussed here have a common causative agent and all present with concomitant infection. Treatment recommendations have changed in recent years with the introduction of plasmapheresis or, more recently, the availability of the antibody eculizumab. Notwithstanding, the most cost-effective measure is withdrawal or switching of the calcineurin inhibitor. TMA is an underdiagnosed clinical entity that should be considered in the management of transplantation patients.

© 2014 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Microangiopatía trombótica asociada a tacrolimus en trasplante pulmonar

R E S U M E N

La microangiopatía trombótica (MAT) es una complicación infrecuente asociada a los anticalcineurínicos en el trasplante pulmonar, independiente de la enfermedad de base de los pacientes trasplantados. Habitualmente se presenta como formas incompletas, lo que dificulta el diagnóstico, que suele ser tardío, provocando irreversibilidad de las lesiones. Es independiente del tiempo de trasplante y en muchos casos existe infección concomitante, lo que tiende a ocultar el diagnóstico. Los casos presentados comparten el agente causal y la presencia de infección concomitante. El tratamiento ha variado en los últimos años, recomendándose la plasmaderesis o, más recientemente, el anticuerpo eculizumab. No obstante, la retirada o cambio del anticalcineurínico causante es la medida más coste-efectiva. La MAT podría tratarse de una entidad infradiagnosticada a tener en cuenta en pacientes trasplantados.

© 2014 SEPAR. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Presentation

Transplant-associated thrombotic microangiopathy (TMA) rarely presents with all 5 of the typical signs–hemolytic anemia, arteriolar and capillary damage, thrombocytopenia, fever and neurological disorders–so clinical suspicion is essential for an early diagnosis.1 There are many predisposing factors for TMA in transplant patients. In addition to infections, calcineurin inhibitors have been identified as causative agents in most cases, and withdrawal of these drugs, along with other measures, has been shown to be the most effective approach.2,3 We report 3 cases of TMA associated with tacrolimus triggered by an infectious process.

Case 1

A 56-year-old man, a single-lung transplant recipient 6 years previously due to emphysema, was admitted due to Nocardia myositis that had formed an abscess in his right leg. Ini-
Table 1
Summary of Changes in Hemoglobin, Creatinine and LDH in the 3 Cases.

<table>
<thead>
<tr>
<th></th>
<th>Initial Hb</th>
<th>TMA Hb</th>
<th>Hb 1 m/post</th>
<th>Schist. PB</th>
<th>Initial creat.</th>
<th>TMA creat.</th>
<th>Creat. 1 m/post</th>
<th>Initial LDH</th>
<th>TMA LDH</th>
<th>LDH 1 m/post</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case 1</td>
<td>12.5 g/dl</td>
<td>7.2 g/dl</td>
<td>9.9 g/dl</td>
<td>Yes (2%)</td>
<td>3.26 mg/dl</td>
<td>7.92 mg/dl</td>
<td>4.93 mg/dl</td>
<td>389 U/l</td>
<td>794 U/l</td>
<td>569 U/l</td>
</tr>
<tr>
<td>Case 2</td>
<td>10.5 g/dl</td>
<td>7.8 g/dl</td>
<td>11 g/dl</td>
<td>Yes</td>
<td>0.82 mg/dl</td>
<td>2.22 mg/dl</td>
<td>1.35 mg/dl</td>
<td>562 U/l</td>
<td>847 U/l</td>
<td>568 U/l</td>
</tr>
<tr>
<td>Case 3</td>
<td>12.1 g/dl</td>
<td>7.0 g/dl</td>
<td>12 g/dl</td>
<td>No</td>
<td>0.73 mg/dl</td>
<td>3.92 mg/dl</td>
<td>0.59 mg/dl</td>
<td>145 000/μl</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Creat.: creatinine; Schist. PB: schistocytes in peripheral blood; Hb: hemoglobin; LDH: lactate dehydrogenate; TMA: thrombotic microangiopathy; 1 m/post: one month after diagnosis of thrombotic microangiopathy.

Discussion

Tacrolimus is a metabolite extracted from the fungus Streptomyces tsukubaensis. It is a potent immunosuppressive agent widely used in transplant procedures. Tacrolimus–associated TMA is a rare, but potentially fatal, complication in solid organ and bone marrow transplantation, with an estimated incidence of 1.0%–4.7%. Early diagnosis is essential for improving treatment outcomes, but it is difficult to achieve due to the existence, on occasions, of previous chronic renal failure (CRF) secondary to calcineurin inhibition. A definitive diagnosis is obtained from the renal biopsy finding of thrombi in the glomerular capillary loops. Treatment of drug-associated TMA is not well defined. Recommendations in the literature are conventionally based on switching the causative medication to sirolimus, everolimus or cyclosporin. If diagnosis is early, effective treatment is available, for example, the antibody eculizumab, or plasmapheresis. No cases of tacrolimus-associated TMA in lung transplant have been published in the Spanish literature, and few have been reported in the international literature. However, this entity may be underdiagnosed, and it should be considered in transplant patients receiving calcineurin inhibitors with deteriorating renal function and unexplained anemia. In our opinion, a kidney biopsy can be avoided if schistocytes are observed in peripheral blood along with low serum haptoglobin levels.

Conflict of Interests

The authors declare they have no conflict of interests.

Acknowledgement

We thank Dr. Pilar Morales for her help.

References